Date:11/13/2008

ic variations, the ability to screen nutritional compounds for their effects on inflammatory responses and other genetic variations, given specific genetic patterns and the ability to make progress in advancing the company's core technologies. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the risk of market acceptance of the company's products, the risk of technology and product obsolescence, delays in product development, the performance of commercial partners, the availability of adequate capital, the actions of competitors and other competitive risks, and those risks and uncertainties described in the company's annual report on Form 10-K, quarterly reports on Form 10-Q and other filings furnished to the Securities and Exchange Commission. The company disclaims any obligation or intention to update these forward-looking statements.

INTERLEUKIN GENETICS, INC. AND SUBSIDIARIES

FINANCIAL HIGHLIGHTS

Balance Sheet Data : 30-Sep 31-Dec

2008 2007

(Unaudited) (Audited)

Cash and cash equivalents $5,914,848 $7,646,468

Total current assets 7,858,834 10,012,508

Total assets $13,345,831 $16,385,949

Total current liabilities $3,435,943 $6,162,535

Total liabilities 7,435,943 6,193,535

Total shareholders' equity 5,909,888 10,192,414

Total liabilities an
'/>"/>

SOURCE Interleukin Genetics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Interleukin Genetics to Present New Findings on Osteoporosis at the 58th Annual Meeting of the American Society of Human Genetics
2. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
3. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
4. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
5. Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results
6. Interleukin Genetics to Present at 2008 BIO International Convention
7. Interleukin Genetics to Present at the 13th International Conference on Periodontal Research
8. Interleukin Genetics Welcomes the Signing of the Genetic Information Nondiscrimination Act (GINA)
9. Interleukin Genetics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
10. Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results
11. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer